Home › Acute Kidney Injury › NCT07670520
Acute Kidney Injury In Care Transitions (ACT): Pragmatic Clinical Trial
Recruiting
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion Criteria: * Clinician subjects * Hospital clinicians including physicians and advanced practice providers employed by Mayo Clinic and practicing at one of the four study sites * Provide care for hospitalized patients with stage 2 or stage 3 acute kidney injury (AKI) who are expected to be discharged home and are not receiving dialysis * Patient subjects: * Adults ≥18 years old * Meet KDIGO consensus criteria for stage 2 (moderate) or 3 (severe) AKI * Residence within the study catchment area (southern Minnesota, northern Iowa, or western Wisconsin) Exclusion Criteria: * Clinician subjects: Physicians and advanced practice providers who: * Care exclusively for pediatric patients (\<18 years) * Care exclusively for patients on palliative care * Patient subjects * Discharged to hospice care * Require outpatient dialysis at discharge * Are admitted from or expected to be discharged to a skilled nursing facility * Dementia Diagnosis * Have undergone solid organ transplant within the past 100 days * Decline authorization for use of their medical records for research
About the study
The purpose of this study is to determine the effect of a multidisciplinary intervention at care transitions for acute kidney injury survivors on patient-centered outcomes.
What is being tested
- Acute Kidney Injury in Care Transitions (ACT) (behavioral)
- Usual Care (behavioral)
Sponsor: Mayo Clinic · Participants: 2,260 · Started: Apr 16, 2026
Contact the study team
- Mitchell C. Strand · Phone: 507-293-0952
Official record on ClinicalTrials.gov — NCT07670520
Locations in the U.S.
| Minnesota | Mayo Clinic Health System-Mankato, Mankato (Not yet recruiting) Mayo Clinic in Rochester, Rochester |
| Wisconsin | Mayo Clinic Health System-Eau Claire Clinic, Eau Claire (Not yet recruiting) |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.